Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa

Two patients with severe sepsis due to panresistant Pseudomonas aeruginosa, deteriorating despite therapy with colistin and β-lactams, were cured with a high daily dose (25 to 50 mg/kg) of amikacin to obtain a peak/MIC ratio of at least 8 to 10 (MIC = 16 μg/ml). Concomitant use of continuous venoven...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy Vol. 54; no. 11; p. 4939
Main Authors: Layeux, Brice, Taccone, Fabio Silvio, Fagnoul, David, Vincent, Jean-Louis, Jacobs, Frédérique
Format: Journal Article
Language:English
Published: United States 01.11.2010
Subjects:
Aged
Amikacin - therapeutic use
Anti-Bacterial Agents - therapeutic use
C-Reactive Protein - metabolism
Creatinine - metabolism
Female
Humans
Male
Middle Aged
Pseudomonas aeruginosa - drug effects
Pseudomonas aeruginosa - pathogenicity
Sepsis - drug therapy
Sepsis - metabolism
Sepsis - microbiology
ISSN:1098-6596, 1098-6596
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Two patients with severe sepsis due to panresistant Pseudomonas aeruginosa, deteriorating despite therapy with colistin and β-lactams, were cured with a high daily dose (25 to 50 mg/kg) of amikacin to obtain a peak/MIC ratio of at least 8 to 10 (MIC = 16 μg/ml). Concomitant use of continuous venovenous hemodiafiltration (CVVHDF) provided no deterioration in renal function after treatment. High dosage of aminoglycosides combined with CVVHDF may represent a valuable therapeutic option for infection due to multiresistant pathogens.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:1098-6596
1098-6596
DOI:10.1128/AAC.00441-10